{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:49:45Z","timestamp":1761094185468,"version":"build-2065373602"},"reference-count":31,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Division of Allergy, Immunology, and Transplantation (DAIT), National Institute of Allergy and Infectious Diseases (NIAID)","award":["UM2 AI 117870","N01-AI25481","HHSN272200900057C","1UMZAI117870"],"award-info":[{"award-number":["UM2 AI 117870","N01-AI25481","HHSN272200900057C","1UMZAI117870"]}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006510","name":"Duke University","doi-asserted-by":"publisher","award":["N01-AI05419","HHSN 272201100025C"],"award-info":[{"award-number":["N01-AI05419","HHSN 272201100025C"]}],"id":[{"id":"10.13039\/100006510","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["DK106829"],"award-info":[{"award-number":["DK106829"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.bbmt.2017.05.018","type":"journal-article","created":{"date-parts":[[2017,6,30]],"date-time":"2017-06-30T21:31:02Z","timestamp":1498858262000},"page":"1463-1472","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Manufacture of Autologous CD34+ Selected Grafts in the NIAID-Sponsored HALT-MS and SCOT Multicenter Clinical Trials for Autoimmune Diseases"],"prefix":"10.1016","volume":"23","author":[{"given":"Carolyn A.","family":"Keever-Taylor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shelly","family":"Heimfeld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaitlyn C.","family":"Steinmiller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard A.","family":"Nash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith M.","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine W.","family":"Czarniecki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomeka C.","family":"Granderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia S.","family":"Goldstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda M.","family":"Griffith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2017.05.018_bib0010","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1212\/WNL.0000000000003660","article-title":"High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS","volume":"88","author":"Nash","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.bbmt.2017.05.018_bib0015","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1001\/jamaneurol.2014.3780","article-title":"High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim report","volume":"72","author":"Nash","year":"2015","journal-title":"JAMA Neurol"},{"issue":"Suppl 10","key":"10.1016\/j.bbmt.2017.05.018_bib0020","first-page":"4363","article-title":"Myeloablative autologous transplantation of CD34+ selected hematopoietic stem cells vs monthly intravenous cyclophosphamide for severe scleroderma with internal organ involvement: outcomes of a randomized North American clinical trial","volume":"68","author":"Sullivan","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.bbmt.2017.05.018_bib0025","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1182\/blood-2003-03-0877","article-title":"Hematopoietic stem cell transplantation for progressive multiple sclerosis: failure of a total body irradiation-based conditioning regimen to prevent disease progression in patients with high disability scores","volume":"102","author":"Burt","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.05.018_bib0030","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1182\/blood-2002-12-3908","article-title":"High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis","volume":"102","author":"Nash","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.05.018_bib0035","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1182\/blood.V100.5.1602.h81702001602_1602_1610","article-title":"High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes","volume":"100","author":"McSweeney","year":"2002","journal-title":"Blood"},{"year":"1999","series-title":"Isolex 300i Magnetic Cell Selector Operator's Manual, Version 2.5CE","author":"Nexell Therapeutics Inc.","key":"10.1016\/j.bbmt.2017.05.018_bib0040"},{"key":"10.1016\/j.bbmt.2017.05.018_bib0045","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1080\/146532401317248081","article-title":"CD34 selection using three immunoselection devices: comparison of T-cell depleted allografts","volume":"3","author":"O'Donnell","year":"2001","journal-title":"Cytotherapy"},{"key":"10.1016\/j.bbmt.2017.05.018_bib0050","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1046\/j.1365-2141.2002.03731.x","article-title":"CD34+-enriched peripheral blood progenitor cells from unrelated donors for allografting of adult patients: high risk of graft failure, infection and relapse despite donor lymphocyte add-back","volume":"118","author":"Bornhauser","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2017.05.018_bib0055","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1046\/j.1365-2141.2002.03561.x","article-title":"Variable product purity and functional capacity after CD34 selection: a direct comparison of the CliniMACS\u00ae (v2.1) and Isolex 300i\u00ae (v2.5) clinical scale devices","volume":"118","author":"Watts","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2017.05.018_bib0060","doi-asserted-by":"crossref","first-page":"488","DOI":"10.3390\/jcm4030488","article-title":"Effects of T-cell depletion on allogeneic hematopoietic stem cell transplantation outcomes in AML patients","volume":"4","author":"Hobbs","year":"2015","journal-title":"J Clin Med"},{"key":"10.1016\/j.bbmt.2017.05.018_bib0065","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1080\/14653240310002298","article-title":"Voluntary accreditation of cellular therapies: Foundation for the Accreditation of Cellular Therapy (FACT)","volume":"5","author":"Warkentin","year":"2003","journal-title":"Cytotherapy"},{"key":"10.1016\/j.bbmt.2017.05.018_bib0070","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/sj.bmt.1702813","article-title":"A European reference protocol for quality assessment and clinical validation of autologous haematopoietic blood progenitor and stem cell grafts","volume":"27","author":"Serke","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.05.018_bib0075","doi-asserted-by":"crossref","first-page":"908","DOI":"10.3324\/haematol.2013.096461","article-title":"Use of the quality management system \u201cJACIE\u201d and outcome after hematopoietic stem cell transplantation","volume":"99","author":"Gratwohl","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2017.05.018_bib0080","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/bjh.14378","article-title":"Optimisation and quality control of cell processing for autologous stem cell transplantation","volume":"175","author":"Watts","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2017.05.018_bib0085","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.bbmt.2016.12.631","article-title":"Storage duration of autologous stem cell preparations has no impact on hematopoietic recovery after transplantation","volume":"23","author":"Lisenko","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.05.018_bib0090","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.bbmt.2011.08.017","article-title":"Characteristics of CliniMACS\u00ae System CD34-enriched T cell-depleted grafts in a multicenter trial for acute myeloid leukemia\u2014Blood and Marrow Transplant Clinical Trials Network (BMT CTN) protocol 0303","volume":"18","author":"Keever-Taylor","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.05.018_bib0095","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1007\/s00277-014-2112-2","article-title":"Factors predicting haematopoietic recovery in patients undergoing autologous transplantation: 11-year experience from a single centre","volume":"93","author":"Bai","year":"2014","journal-title":"Ann Hematol"},{"key":"10.1016\/j.bbmt.2017.05.018_bib0100","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1002\/art.10495","article-title":"A pilot randomized trial comparing CD34-selected versus unmanipulated hemopoietic stem cell transplantation for severe, refractory rheumatoid arthritis","volume":"46","author":"Moore","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.bbmt.2017.05.018_bib0105","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/bmt.2015.299","article-title":"Does ex vivo CD34+ positive selection influence outcome after autologous hematopoietic stem cell transplantation in systemic sclerosis patients?","volume":"51","author":"Oliveira","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.05.018_bib0110","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/S0140-6736(16)30169-6","article-title":"Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial","volume":"388","author":"Atkins","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2017.05.018_bib0115","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1212\/WNL.0000000000001329","article-title":"Autologous hematopoietic stem cell transplantation in multiple sclerosis: a phase II trial","volume":"84","author":"Mancardi","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.bbmt.2017.05.018_bib0120","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1177\/1352458511429320","article-title":"Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: the Italian multi-centre experience","volume":"18","author":"Mancardi","year":"2012","journal-title":"Mult Scler"},{"key":"10.1016\/j.bbmt.2017.05.018_bib0125","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1136\/jnnp-2013-307207","article-title":"Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience","volume":"85","author":"Burman","year":"2014","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.bbmt.2017.05.018_bib0130","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1001\/jama.2014.17986","article-title":"Association of nonmyeloablative hematopoietic stem cell transplantation with neurological disability in patients with relapsing-remitting multiple sclerosis","volume":"313","author":"Burt","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.bbmt.2017.05.018_bib0135","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1001\/jama.2014.6368","article-title":"Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial","volume":"311","author":"van Laar","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.bbmt.2017.05.018_bib0140","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S0140-6736(11)60982-3","article-title":"Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial","volume":"378","author":"Burt","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2017.05.018_bib0145","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1001\/jamaneurol.2016.5867","article-title":"Long-term outcomes after autologous hematopoietic stem cell transplantation for multiple sclerosis","volume":"74","author":"Muraro","year":"2017","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.bbmt.2017.05.018_bib0150","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1084\/jem.20041679","article-title":"Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients","volume":"201","author":"Muraro","year":"2005","journal-title":"J Exp Med"},{"key":"10.1016\/j.bbmt.2017.05.018_bib0155","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1172\/JCI71691","article-title":"T cell repertoire following autologous stem cell transplantation for multiple sclerosis","volume":"124","author":"Muraro","year":"2014","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bbmt.2017.05.018_bib0160","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/ana.23784","article-title":"Diminished Th17 (not Th1) responses underlie multiple sclerosis disease abrogation after hematopoietic stem cell transplantation","volume":"73","author":"Darlington","year":"2013","journal-title":"Ann Neurol"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879117304652?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879117304652?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:58:02Z","timestamp":1761058682000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879117304652"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S1083879117304652"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2017.05.018","relation":{},"ISSN":["1083-8791"],"issn-type":[{"type":"print","value":"1083-8791"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Manufacture of Autologous CD34+ Selected Grafts in the NIAID-Sponsored HALT-MS and SCOT Multicenter Clinical Trials for Autoimmune Diseases","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2017.05.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of the American Society for Blood and Marrow Transplantation.","name":"copyright","label":"Copyright"}]}}